Enrica Cavedo1, Alberto Redolfi2, Francesco Angeloni3, Claudio Babiloni4, Roberta Lizio5, Luisa Chiapparini6, Maria G Bruzzone6, Domenico Aquino6, Umberto Sabatini7, Marcella Alesiani7, Andrea Cherubini7, Elena Salvatore8, Andrea Soricelli9, Fabrizio Vernieri10, Federica Scrascia10, Elena Sinforiani11, Patrizia Chiarati11, Stefano Bastianello11, Patrizia Montella12, Daniele Corbo12, Gioacchino Tedeschi12, Silvia Marino13, Annalisa Baglieri13, Simona De Salvo13, Filippo Carducci14, Carlo C Quattrocchi15, Milena Cobelli16, Giovanni B Frisoni17. 1. LENITEM Laboratory of Epidemiology, Neuroimaging, & Telemedicine - IRCCS Centro San Giovanni di Dio-FBF, Brescia, Italy Cognition, Neuroimaging and Brain Diseases Laboratory, Centre de Recherche de l'Institut du Cerveau et de la Moelle Épinière (CRICM-UMRS 975), Université Pierre et Marie Curie-Paris, France. 2. LENITEM Laboratory of Epidemiology, Neuroimaging, & Telemedicine - IRCCS Centro San Giovanni di Dio-FBF, Brescia, Italy. 3. IRCCS Fondazione SDN per la Ricerca e l'Alta Formazione in Diagnostica Nucleare, Naples, Italy. 4. Laboratory of High resolution EEG, Department of Physiology and Pharmacology, University of Rome "La Sapienza", Rome, Italy IRCCS San Raffaele Pisana, Rome, Italy. 5. IRCCS San Raffaele Pisana, Rome, Italy. 6. Neuroradiology Unit, Fondazione IRCCS Istituto Neurologico "Carlo Besta," Milan, Italy. 7. Santa Lucia Foundation, Radiology Department, Rome, Italy. 8. Department of Neurosciences, Reproductive Sciences and Odontostomatology, University Of Naples Federico II, Naples, Italy. 9. IRCCS Fondazione SDN per la Ricerca e l'Alta Formazione in Diagnostica Nucleare, Naples, Italy Department of Studies of Institutions and Territorial Systems, University of Naples Parthenope, Naples, Italy. 10. Neurol. University "Campus Biomedico" Rome, Italy. 11. IRCCS C. Mondino National Institute of Neurology Foundation and University of Pavia, Pavia, Italy. 12. Department of Neurological Sciences, Second University of Naples, Naples, Italy. 13. IRCCS Centro Neurolesi "Bonino-Pulejo", Messina, Italy. 14. Laboratory of Neuroimaging, Department of Physiology and Pharmacology, University of Rome "La Sapienza", Rome, Italy. 15. IRCCS "Ospedale Pediatrico Bambino Gesù", Roma, Italy. 16. Neuroradiology Unit, Fondazione Poliambulanza, Brescia, Italy. 17. LENITEM Laboratory of Epidemiology, Neuroimaging, & Telemedicine - IRCCS Centro San Giovanni di Dio-FBF, Brescia, Italy Memory Clinic and LANVIE - Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland.
Abstract
BACKGROUND: The North American Alzheimer's Disease Neuroimaging Initiative (NA-ADNI) was the first program to develop standardized procedures for Alzheimer's disease (AD) imaging biomarker collection. OBJECTIVE: We describe the validation of acquisition and processing of structural magnetic resonance imaging (MRI) in different Italian academic AD clinics following NA-ADNI procedures. METHODS: 373 patients with subjective memory impairment (n = 12), mild cognitive impairment (n = 92), Alzheimer's dementia (n = 253), and frontotemporal dementia (n = 16) were enrolled in 9 Italian centers. 22 cognitively healthy elderly controls were also included. MRI site qualification and MP-RAGE quality assessment was applied following the NA-ADNI procedures. Indices of validity were: (i) NA-ADNI phantom's signal-to-noise and contrast-to-noise ratio, (ii) proportion of images passing quality control, (iii) comparability of automated intracranial volume (ICV) estimates across scanners, and (iv) known-group validity of manual hippocampal volumetry. RESULTS: Results on Phantom and Volunteers scans showed that I-ADNI acquisition parameters were comparable with those one of the ranked-A ADNI scans. Eighty-seven percent of I-ADNI MPRAGE images were ranked of high quality in comparison of 69% of NA-ADNI. ICV showed homogeneous variances across scanners except for Siemens scanners at 3.0 Tesla (p = 0.039). A significant difference in hippocampal volume was found between AD and controls on 1.5 Tesla scans (p < 0.001), confirming known group validity test. CONCLUSION: This study has provided standardization of MRI acquisition and imaging marker collection across different Italian clinical units and equipment. This is a mandatory step to the implementation of imaging biomarkers in clinical routine for early and differential diagnosis.
BACKGROUND: The North American Alzheimer's Disease Neuroimaging Initiative (NA-ADNI) was the first program to develop standardized procedures for Alzheimer's disease (AD) imaging biomarker collection. OBJECTIVE: We describe the validation of acquisition and processing of structural magnetic resonance imaging (MRI) in different Italian academic AD clinics following NA-ADNI procedures. METHODS: 373 patients with subjective memory impairment (n = 12), mild cognitive impairment (n = 92), Alzheimer's dementia (n = 253), and frontotemporal dementia (n = 16) were enrolled in 9 Italian centers. 22 cognitively healthy elderly controls were also included. MRI site qualification and MP-RAGE quality assessment was applied following the NA-ADNI procedures. Indices of validity were: (i) NA-ADNI phantom's signal-to-noise and contrast-to-noise ratio, (ii) proportion of images passing quality control, (iii) comparability of automated intracranial volume (ICV) estimates across scanners, and (iv) known-group validity of manual hippocampal volumetry. RESULTS: Results on Phantom and Volunteers scans showed that I-ADNI acquisition parameters were comparable with those one of the ranked-A ADNI scans. Eighty-seven percent of I-ADNI MPRAGE images were ranked of high quality in comparison of 69% of NA-ADNI. ICV showed homogeneous variances across scanners except for Siemens scanners at 3.0 Tesla (p = 0.039). A significant difference in hippocampal volume was found between AD and controls on 1.5 Tesla scans (p < 0.001), confirming known group validity test. CONCLUSION: This study has provided standardization of MRI acquisition and imaging marker collection across different Italian clinical units and equipment. This is a mandatory step to the implementation of imaging biomarkers in clinical routine for early and differential diagnosis.
Authors: E Cavedo; S Lista; Z Khachaturian; P Aisen; P Amouyel; K Herholz; C R Jack; R Sperling; J Cummings; K Blennow; S O'Bryant; G B Frisoni; A Khachaturian; M Kivipelto; W Klunk; K Broich; S Andrieu; M Thiebaut de Schotten; J-F Mangin; A A Lammertsma; K Johnson; S Teipel; A Drzezga; A Bokde; O Colliot; H Bakardjian; H Zetterberg; B Dubois; B Vellas; L S Schneider; H Hampel Journal: J Prev Alzheimers Dis Date: 2014-12
Authors: Harald Hampel; Nicola Toschi; Claudio Babiloni; Filippo Baldacci; Keith L Black; Arun L W Bokde; René S Bun; Francesco Cacciola; Enrica Cavedo; Patrizia A Chiesa; Olivier Colliot; Cristina-Maria Coman; Bruno Dubois; Andrea Duggento; Stanley Durrleman; Maria-Teresa Ferretti; Nathalie George; Remy Genthon; Marie-Odile Habert; Karl Herholz; Yosef Koronyo; Maya Koronyo-Hamaoui; Foudil Lamari; Todd Langevin; Stéphane Lehéricy; Jean Lorenceau; Christian Neri; Robert Nisticò; Francis Nyasse-Messene; Craig Ritchie; Simone Rossi; Emiliano Santarnecchi; Olaf Sporns; Steven R Verdooner; Andrea Vergallo; Nicolas Villain; Erfan Younesi; Francesco Garaci; Simone Lista Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: R Sacco; A Bisecco; D Corbo; M Della Corte; A d'Ambrosio; R Docimo; A Gallo; F Esposito; S Esposito; M Cirillo; L Lavorgna; G Tedeschi; S Bonavita Journal: J Neurol Date: 2015-05-10 Impact factor: 4.849
Authors: Yasamin Salimi; Daniel Domingo-Fernández; Carlos Bobis-Álvarez; Martin Hofmann-Apitius; Colin Birkenbihl Journal: Alzheimers Res Ther Date: 2022-05-21 Impact factor: 8.823
Authors: Emma Lawrence; Carolin Vegvari; Alison Ower; Christoforos Hadjichrysanthou; Frank De Wolf; Roy M Anderson Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472